Public policy plays a critical role in ensuring patients have access to plasma-derived medicinal products. A resilient plasma supply is the result of thoughtful, science-based and data-driven policy decisions.
Regulations and policies that recognize the unique nature of plasma collection, manufacturing complexity, and global supply dependencies help support a stable plasma supply chain. When these factors are overlooked it can create barriers to access and treatment disruptions for patients.
Collaboration between industry experts, health care professionals, patient organizations, regulators, and policymakers is essential to building informed policies that prioritize patient needs while maintaining donor safety and product quality.